Clinical Trial: The Effects of Buproprion on Residual and Cognitive Symptoms in SSRI-Treated Depression.

This study is currently recruiting patients.
Verified by Mclean Hospital August 2005

Sponsors and Collaborators: Mclean Hospital
National Association for Research on Schizophrenia and Affective Disorders.
Information provided by: Mclean Hospital Identifier: NCT00125957


Many people with depression are treated with a serotonin-specific reuptak inhibitor anti-depressant (SSRI) and feel ''''better''''. Although many people feel ''''better'''', they do not feel completely ''''well''''. Often, individuals continue to complain of cognitive problems such as lack of attention, diminished motivation, and impaired problem-solving. This study looks at whether residual and cognitive symptoms of depression in individuals is affected by the addition of buproprion.
Condition Intervention Phase
Major Depressive Disorder
Unipolar Depression
 Drug: buproprion
Phase III

MedlinePlus related topics:  Depression;   Mental Health

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study

Further Study Details: 
Primary Outcomes: MADRS overall and question-specific scores; neuropsychiatric assessment changes; hyperactivity measures
Secondary Outcomes: self-report
Expected Total Enrollment:  30

Study start: August 2005;  Expected completion: August 2006
Last follow-up: August 2006;  Data entry closure: August 2006

As many as 65-75% of treated patients continue to experience residual symtoms of depression. Cognitive impairments feature frontal cognitive dysfunction. Many experts believe that executive functions are better predictors of functional level than psychiatric diagnosis.

Frontal cognitive impairment and changes in neuroimaging is seen in individuals depleted of tryptophan, a serotonin precursor. These cognitive changes do not improve following serotonin-specific reuptake inhibitor treatment and at least one study has found that executive dysfunction predicts non-response to fluoxetine. In many patients, remission of mood symptoms in depression requires medications to target non-serotonergic neurotransmitter systems. Brain areas mediating executive functions receive rich noradrenergic inputs, and norepinephrine is known to be intimately involved in many of the executive functions.

A better understanding of serotonergic and catecholaminergic interactions would enable evidence-based treatment of depression which maximizes executive cognitive functions. This study examines the hypothesis that invididuals treated with buproprion will have higher scores on tests of executive functions and lower scores on depression indices.


Ages Eligible for Study:  18 Years   -   70 Years,  Genders Eligible for Study:  Both

Inclusion Criteria: depression SSRI-treated

Exclusion Criteria: bipolar disorder SNRI or buproprion treatment treatment-resistant depression seizure disorder bulimia or anorexia nervosa pregnancy

Location and Contact Information

Please refer to this study by identifier  NCT00125957

Tara M      617-855-2988 

      McLean Hospital, Belmont,  Massachusetts,  02478,  United States; Recruiting
Tara M  617-855-2988 
Beth L Murphy, MD, PhD,  Principal Investigator
J. Alexander Bodkin, MD,  Sub-Investigator

Study chairs or principal investigators

Beth L Murphy, MD, PhD,  Principal Investigator,  Mclean Hospital   

More Information

Study ID Numbers:  2005P-000502
Last Updated:  August 1, 2005
Record first received:  August 1, 2005 Identifier:  NCT00125957
Health Authority: United States: Institutional Review Board processed this record on 2005-08-02

Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us